Literature DB >> 30897406

Determination of eumelanin and pheomelanin in melanomas using solid-phase extraction and high performance liquid chromatography-diode array detection (HPLC-DAD) analysis.

Benjamin Rioux1, Jacques Rouanet1, Hussein Akil1, Sophie Besse1, Eric Debiton1, Bernadette Bouchon1, Françoise Degoul1, Mercedes Quintana2.   

Abstract

Determination of eumelanin and pheomelanin in melanomas that exhibit different pigmentation was carried using a solid-phase extraction (SPE) preparation method based on weak anion exchange chemistry. This extraction significantly enhanced the chromatographic profile obtained by reverse phase high performance liquid chromatography-diode array detection (RP-HPLC-DAD). The SPE method was developed using aqueous standards of melanin markers: thiazole-2,4,5-tricarboxylic acid (TTCA), thiazole-4,5-dicarboxylic acid (TDCA), pyrrole-2,3-dicarboxylic acid (PDCA) and pyrrole-2,3,5-tricarboxylic acid (PTCA) and non-pigmented cell lines spiked with those markers. An excellent average recovery, above 90%, was obtained for the four markers with a relative standard deviation below 7%. We have also optimized the stationary phase and the mobile phase (phosphate concentration and pH) to improve sensitivity and to reduce the analysis time. Elution of the four markers is achieved in 5 min and total analysis of biological samples is completed in 15 min. The quantification limits for TDCA, TTCA, PDCA and PTCA are 60, 50, 47 and 48 ng/mL respectively. Furthermore, DAD detection improves the marker identification in complex matrices through the analysis of UV spectra. We have successfully applied this method to melanoma tumors and cells. Murine B16BL6 tumor are highly pigmented with mostly eumelanin (98.1% of eumelanin) while human SK-MEL-3 tumor contain about 30% pheomelanin. B16BL6 and B16F10 are eumelanic cells lines and NHEM melanocytes contain about 24% of pheomelanin.
Copyright © 2019 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Eumelanin; High performance liquid chromatography–diode array detection (HPLC-DAD); Melanoma tumors; Pheomelanin; Solid-phase extraction (SPE)

Mesh:

Substances:

Year:  2019        PMID: 30897406     DOI: 10.1016/j.jchromb.2019.03.010

Source DB:  PubMed          Journal:  J Chromatogr B Analyt Technol Biomed Life Sci        ISSN: 1570-0232            Impact factor:   3.205


  5 in total

1.  Targeted Radionuclide Therapy Decreases Melanoma Lung Invasion by Modifying Epithelial-Mesenchymal Transition-Like Mechanisms.

Authors:  Hussein Akil; Jacques Rouanet; Claire Viallard; Sophie Besse; Philippe Auzeloux; Jean-Michel Chezal; Elisabeth Miot-Noirault; Mercedes Quintana; Françoise Degoul
Journal:  Transl Oncol       Date:  2019-08-14       Impact factor: 4.243

2.  Preferential stimulation of melanocytes by M2 macrophages to produce melanin through vascular endothelial growth factor.

Authors:  Heeju Han; Yena Kim; Hyunkyung Mo; Si Hwa Choi; Kijun Lee; Yeri Alice Rim; Ji Hyeon Ju
Journal:  Sci Rep       Date:  2022-04-19       Impact factor: 4.996

3.  Improved HPLC Conditions to Determine Eumelanin and Pheomelanin Contents in Biological Samples Using an Ion Pair Reagent.

Authors:  Shosuke Ito; Sandra Del Bino; Tomohisa Hirobe; Kazumasa Wakamatsu
Journal:  Int J Mol Sci       Date:  2020-07-20       Impact factor: 5.923

4.  Quantitation of eumelanin and pheomelanin markers in diverse biological samples by HPLC-UV-MS following solid-phase extraction.

Authors:  Susanne Affenzeller; Holm Frauendorf; Tobias Licha; Daniel J Jackson; Klaus Wolkenstein
Journal:  PLoS One       Date:  2019-10-17       Impact factor: 3.240

5.  Efficacy of Targeted Radionuclide Therapy Using [131I]ICF01012 in 3D Pigmented BRAF- and NRAS-Mutant Melanoma Models and In Vivo NRAS-Mutant Melanoma.

Authors:  Hussein Akil; Mercedes Quintana; Jérémy H Raymond; Tommy Billoux; Valentin Benboubker; Sophie Besse; Philippe Auzeloux; Véronique Delmas; Valérie Petit; Lionel Larue; Michel D'Incan; Françoise Degoul; Jacques Rouanet
Journal:  Cancers (Basel)       Date:  2021-03-20       Impact factor: 6.639

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.